The Ofichem Group has announced a definitive agreement to acquire Kinentia Biosciences, a Rensselaer, New York-based Drug Substance Contract Development and Manufacturing Organization (CDMO). The strategic acquisition marks a significant expansion of the Netherlands-based group’s footprint, providing a bridge between its established European manufacturing infrastructure and the burgeoning U.S. biotechnology market.
The move comes as global pharmaceutical companies are increasingly prioritizing supply chain resilience, seeking partners that offer regional flexibility and diversified manufacturing nodes. By integrating Kinentia into its operations, Ofichem aims to create a cohesive, global organization capable of supporting clients from initial early-stage development through to full-scale commercial supply.
“The acquisition of Kinentia represents an important milestone in Ofichem’s continued development,” said Dr. Weite Oldenziel, CEO of the Ofichem Group. “It strengthens our presence in the United States and complements our established European development and manufacturing capabilities. We are building one organization with one knowledge base, able to support customers from the first development decisions through to commercial supply.”
Kinentia, which has provided specialized early-stage development and preclinical support since 2007, will gain access to the wider Ofichem network. This includes the group’s FDA-inspected GMP manufacturing facility in Ter Apel, Netherlands, as well as analytical and regulatory support services. For existing Kinentia clients, the partnership creates a seamless path to scale-up as their drug programs advance.
Beyond expanding current service offerings, the acquisition serves as a platform for Ofichem’s future ambitions in the U.S. market, particularly regarding highly regulated products. The company plans to explore opportunities to establish domestic capabilities for controlled substances, leveraging the expertise Ofichem has already cultivated in Europe.
The deal also significantly broadens the company’s scientific portfolio. Kinentia’s expertise in polysaccharides, small peptides, and complex new chemical entities will integrate with Ofichem’s existing proficiencies in small molecules, highly potent compounds (OEB 3-5), oligonucleotides, and PROTAC-based targeted protein degradation.
Following the completion of the acquisition, the combined Drug Substance business will operate across sites in New York, Ter Apel, and Uppsala, Sweden. This geographical spread is designed to provide customers with greater flexibility in where they conduct their development and manufacturing activities, a critical factor in today’s volatile global market.
Dr. Dave Fairfax, President and CEO of Kinentia, expressed optimism regarding the integration. “For our team and our customers, the fit with Ofichem is strong,” said Fairfax. “We share a commitment to quality, scientific expertise, and long-term customer relationships. Joining the group gives Kinentia access to a wider scientific network and a route into commercial manufacturing, while preserving the specialist approach that has shaped our business.”
The transaction underscores a broader industry trend of consolidation, as CDMOs seek to offer end-to-end solutions that satisfy the increasing demand for regional, agile, and resilient supply chains.
Disclaimer: This content is auto-generated for informational purposes only.
Source: Read Original News
